Skip to main content
Figure 4 | BMC Gastroenterology

Figure 4

From: Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis

Figure 4

Clinical, macroscopic, and histopathological changes following treatment with lentivirus vector encoding mouse interleukin 10 (mIL-10). (a) CDA score was monitored 3 day per a week. Each point represents the mean ± SD. Balb/c mice received Mock or LV encoding mIL-10 (LV mIL-10) once or twice by rectal administration. There is a significant difference between Mock and both LV mIL-10 (1) and (2), however no difference between LVmIL-10(1) and (2) on Days 10 and 24. All values were expressed as mean s ± SD. Statistically significant differences are shown. *P < 0.05. (b) Changes in macroscopic colonic damage scores of 3% DSS colitis treated with LV encoding mIL-10. Macroscopic colonic damage score of mock-treated, LV once-treatment/DSS exposure group (LV(1)) or LV twice-treatment/DSS exposure group (LV(2)) compared to no treatment groups (n = 8/group) are shown for each of the two DSS exposures on Day 10 or Day 32. All values were expressed as mean ± SD. Statically significant differences are shown. *p < 0.05. (c) Changes in histologic scoring of 3% DSS colitis treated by LV encoding mIL-10. The degree of histological injury following DSS exposure on Day 10 and Day 32 are shown for mock-treated, LV once-treatment/DSS exposure group (LV(1)) or LV twice-treatment/DSS exposure group (LV(2)) compared to no treatment groups (n = 8/group). All values were expressed as mean ± SD. Statically significant differences are shown. *p < 0.05.

Back to article page